1. A polymorphic form of the compound I or a pharmaceutically acceptable salt or a polymorph solvatapredstavlyayuschaya I p-toluenesulfonate 1/1 compounds I, wherein polymorph Form I has from 1 to 3 characteristic peaks in a powder X-ray diffraction pattern selected from the group consisting of 13.182 ± 0.2 °, 0.2 ± 21.472 ° and 22.833 ° ± 0.2 .2. The polymorphic form according to Claim. 1, having a maximum peak at 231,5-237,7 ° C on the chart of differential scanning kalorimetrii.3. Polymorphic form of the compound I or a pharmaceutically acceptable salt or polymorph solvatapredstavlyayuschaya a methanol solvate II p-toluenesulfonate 1/1 compound I (1: 1: 1), the polymorph Form II has from 1 to 3 characteristic peaks in a powder X-ray diffractogram, selected from the group consisting of 21.014 ° ± 0.2, 0.2 ± 18.333 ° and 25.301 ° ± 0.2 .4. Polymorphic form according to claim. 3, having a maximum peak at 193,5-197,0 ° C and 228,6-236,4 ° C on the chart of differential scanning kalorimetrii.5. Polymorphic form of the compound I or a pharmaceutically acceptable salt or a polymorph solvatapredstavlyayuschaya III 1/1 p-toluenesulfonate compound I, wherein polymorph Form III is 1 or 2, the characteristic peak in the powder X-ray diffraction pattern selected from the group consisting of 19,858 ± 0 2 ° and 25.896 ° ± 0.2 .6. Polymorphic form according to claim. 5 having the maximum peak at 193,8-197,2 ° C and 231,3-236,9 ° C on the chart of differential scanning kalorimetrii.7. Polymorphic form of the compound I or a pharmaceutically acceptable salt or a polymorph solvatapredstavlyayuschaya IV ethanol solvate p-toluenesulfonate 1/1 I compound, wherein the polymorph Form IV has 1 or 2 of the characteristic peak in the powder X-ray diffraction pattern selected from the group consisting of 20,961 ± 0,2 ° and 0,2 ° 18.277 ± .8. polymorphic1. Полиморфная форма соединения I или его фармацевтически приемлемой соли или сольватапредставляющая собой полиморфную форму I п-толуолсульф
